Clinical trial NCT00026091: Fenretinide in Treating Patients With Recurrent or Metastatic Ovarian Epithelial or Primary Peritoneal Cancer
Official title: Phase II Trial of Fenretinide (NSC 374551) in Recurrent Ovarian Cancer and Primary Peritoneal Carcinoma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Recurrent Ovarian Epithelial Cancer
Recurrent Primary Peritoneal Cavity Cancer
Stage IV Ovarian Epithelial Cancer
Stage IV Primary Peritoneal Cavity Cancer
Lead sponsor: National Cancer Institute (NCI)
Sponsor class: NIH
First posted: 2003-01-27
Enrollment: 40
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Phase II trial to study the effectiveness of fenretinide in treating patients who have recurrent or metastatic ovarian epithelial or primary peritoneal cancer. Drugs used in chemotherapy, such as fenretinide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing

Detailed description: PRIMARY OBJECTIVES:

I. To evaluate the efficacy of fenretinide (4-HPR) in patients with recurrent ovarian cancer or primary peritoneal carcinoma.

II. To assess the toxicity of this agent in this patient population. III. To evaluate molecular changes in normal and tumor cells induced by 4-HPR by studying: (a) the analysis of ceramide and glucosyleceramide levels before and after therapy, (b) intracellular levels of 4-HPR and 4-MPR, and (c) determinants of apoptosis (p53, p21, bcl-2, bax and terminal deoxynucleotidyl transferase \[TdT\] assay) in baseline tumor specimens, serial serum and tumor biopsy specimens where available, and surrogate in-vitro studies.

IV. To evaluate the pharmacokinetics of fenretinide. V. To further investigate the antiangiogenesis effects of fenretinide in in-vitro assays using ovarian cancer cell lines and in vascular growth factor (VEGF, TGFb) plasma levels in patients.

OUTLINE:

Patients receive oral fenretinide twice daily on days 1-7. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.

Eligibility criteria: Inclusion Criteria:

* Patients with histologically confirmed recurrent or metastatic epithelial ovarian cancer or primary peritoneal carcinoma
* Unidimensionally measurable disease; indicator lesions must not have been irradiated unless they have grown following radiation therapy
* SWOG performance status 0-2
* Patients must have received a platinum and paclitaxel containing regimen
* Patients are allowed to receive =\< 2 prior chemotherapy regimens for recurrent disease; patients who are rechallenged with the same chemotherapy regimen are considered to have had that regimen only once
* Projected life expectancy must be at least 3 months
* Signed informed consent
* Absolute neutrophil count \>= 1500/ul
* Platelet count \>= 100,000 ul
* Bilirubin =\< 2 times the institutional limit of normal
* ALT or AST =\< 3 times the upper limit of normal
* Measured or calculated creatinine clearance \>= 60 ml/min
* Fasting triglycerides =\< 1 time the upper limit of normal; triglycerides may be "normalized" prior to study entry with use of an antilipemic agent (atorvastatin, fenofibrate)
* Patients must have recovered from acute toxicities from surgery, radiation or chemotherapy; at least 3 weeks will have elapsed since any prior therapy directed at the malignant tumor
* Patients of childbearing potential must agree to use an approved method of birth control

Exclusion Criteria:

* Prior fenretinide is not allowed; prior 13-cis, 9-cis or all-transretinoic acid are allowed
* Patients with a second malignancy within the last 5 years are not allowed, except for those with non-melanomatous skin cancer and carcinoma-in-situ of the cervix; all prior invasive malignancies must be in complete remission
* The use of concomitant antioxidants, such as vitamin C or E, is not allowed
* Patients with concurrent medical, psychological or social conditions of such severity that the investigator deems it unwise to enter the patient on protocol
* Untreated or symptomatic brain metastases
* Pregnant or nursing women

Primary outcomes:
measure: Response rate (CR or PR)
timeFrame: Up to 9 years
Secondary outcomes:
measure: Time to treatment failure
timeFrame: up to 9 years
measure: Duration of response
timeFrame: From the time measurement criteria met for CR/PR until the first date that recurrent or progressive disease is objectively documented, assessed up to 9 years
measure: Overall survival
timeFrame: From first day of treatment to time of death due to any cause, assessed up to 9 years
measure: Toxicity
timeFrame: Up to 9 years after completion of treatment
measure: Pharmacokinetics of fenretinide
timeFrame: Baseline. day 1, 4 and 7 of courses 1, day 1 of courses 2, 5, and 9, day 7 of courses 4 and 8
measure: Molecular change
timeFrame: Baseline to end of treatment
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: University of Southern California
state: California
Study officials:
affiliation: University of Southern California
name: Agustin Garcia
role: PRINCIPAL_INVESTIGATOR
References: